Forming megakaryocytes from murine-induced pluripotent stem cells by the inducible overexpression of supporting factors.
Genetic modification
Tet‐inducible system
iPS cells
megakaryocytes
retroviral vectors
Journal
Research and practice in thrombosis and haemostasis
ISSN: 2475-0379
Titre abrégé: Res Pract Thromb Haemost
Pays: United States
ID NLM: 101703775
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
21
09
2020
accepted:
24
09
2020
entrez:
4
2
2021
pubmed:
5
2
2021
medline:
5
2
2021
Statut:
epublish
Résumé
Platelets are small anucleate cells that circulate in the blood in a resting state but can be activated by external cues. In case of need, platelets from blood donors can be transfused. As an alternative source, platelets can be produced from induced pluripotent stem cells (iPSCs); however, recovered numbers are low. To optimize megakaryocyte (MK) and platelet output from murine iPSCs, we investigated overexpression of the transcription factors GATA-binding factor 1 (GATA1); nuclear factor, erythroid 2; and pre-B-cell leukemia transcription factor 1 (Pbx1) and a hyperactive variant of the small guanosine triphosphatase RhoA (RhoAhc). To avoid off-target effects, we generated iPSCs carrying the reverse tetracycline-responsive transactivator M2 (rtTA-M2) in the Rosa26 locus and expressed the factors from Tet-inducible gammaretroviral vectors. Differentiation of iPSCs was initiated by embryoid body (EB) formation. After EB dissociation, early hematopoietic progenitors were enriched and cocultivated on OP9 feeder cells with thrombopoietin and stem cell factor to induce megakaryocyte (MK) differentiation. Overexpression of GATA1 and Pbx1 increased MK output 2- to 2.5-fold and allowed prolonged collection of MK. Cytologic and ultrastructural analyses identified typical MK with enlarged cells, multilobulated nuclei, granule structures, and an internal membrane system. However, GATA1 and Pbx1 expression did not improve MK maturation or platelet release, although in vitro-generated platelets were functional in spreading on fibrinogen or collagen-related peptide. We demonstrate that the use of rtTA-M2 transgenic iPSCs transduced with Tet-inducible retroviral vectors allowed for gene expression at later time points during differentiation. With this strategy we could identify factors that increased in vitro MK production.
Sections du résumé
BACKGROUND
BACKGROUND
Platelets are small anucleate cells that circulate in the blood in a resting state but can be activated by external cues. In case of need, platelets from blood donors can be transfused. As an alternative source, platelets can be produced from induced pluripotent stem cells (iPSCs); however, recovered numbers are low.
OBJECTIVES
OBJECTIVE
To optimize megakaryocyte (MK) and platelet output from murine iPSCs, we investigated overexpression of the transcription factors GATA-binding factor 1 (GATA1); nuclear factor, erythroid 2; and pre-B-cell leukemia transcription factor 1 (Pbx1) and a hyperactive variant of the small guanosine triphosphatase RhoA (RhoAhc).
METHODS
METHODS
To avoid off-target effects, we generated iPSCs carrying the reverse tetracycline-responsive transactivator M2 (rtTA-M2) in the Rosa26 locus and expressed the factors from Tet-inducible gammaretroviral vectors. Differentiation of iPSCs was initiated by embryoid body (EB) formation. After EB dissociation, early hematopoietic progenitors were enriched and cocultivated on OP9 feeder cells with thrombopoietin and stem cell factor to induce megakaryocyte (MK) differentiation.
RESULTS
RESULTS
Overexpression of GATA1 and Pbx1 increased MK output 2- to 2.5-fold and allowed prolonged collection of MK. Cytologic and ultrastructural analyses identified typical MK with enlarged cells, multilobulated nuclei, granule structures, and an internal membrane system. However, GATA1 and Pbx1 expression did not improve MK maturation or platelet release, although in vitro-generated platelets were functional in spreading on fibrinogen or collagen-related peptide.
CONCLUSION
CONCLUSIONS
We demonstrate that the use of rtTA-M2 transgenic iPSCs transduced with Tet-inducible retroviral vectors allowed for gene expression at later time points during differentiation. With this strategy we could identify factors that increased in vitro MK production.
Identifiants
pubmed: 33537535
doi: 10.1002/rth2.12453
pii: S2475-0379(22)01304-8
pmc: PMC7845061
doi:
Types de publication
Journal Article
Langues
eng
Pagination
111-124Informations de copyright
© 2020 The Authors. Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis (ISTH).
Références
Blood. 2014 Sep 18;124(12):1857-67
pubmed: 25606631
Exp Hematol. 2002 Jan;30(1):49-57
pubmed: 11823037
Hum Gene Ther. 2005 Nov;16(11):1241-6
pubmed: 16259557
Nat Commun. 2016 Apr 07;7:11208
pubmed: 27052461
Exp Hematol. 2008 Jan;36(1):78-92
pubmed: 17923245
Cell. 2005 May 6;121(3):465-77
pubmed: 15882627
Curr Protoc Stem Cell Biol. 2008 Jul;Chapter 1:Unit 1F.4
pubmed: 18770633
Transfusion. 2007 Mar;47(3):385-94
pubmed: 17319817
Stem Cell Reports. 2018 Dec 11;11(6):1462-1478
pubmed: 30503262
Blood. 2008 Jun 1;111(11):5298-306
pubmed: 18388179
Platelets. 2020 Aug 17;31(6):724-730
pubmed: 32486997
Blood. 2012 Jan 26;119(4):1054-63
pubmed: 22045984
Mol Ther. 2011 Apr;19(4):782-9
pubmed: 21285961
Cell. 1995 Jun 2;81(5):695-704
pubmed: 7774011
Methods Mol Biol. 2012;788:205-17
pubmed: 22130710
Stem Cells Dev. 2012 Mar 20;21(5):689-701
pubmed: 21732815
Hum Gene Ther. 2011 Feb;22(2):166-76
pubmed: 20825282
Sci Rep. 2018 Jul 5;8(1):10146
pubmed: 29977045
Mol Cell Biol. 1993 Jan;13(1):473-86
pubmed: 8417345
Blood. 1995 Jan 15;85(2):402-13
pubmed: 7529062
Br J Haematol. 2015 Nov;171(3):297-305
pubmed: 26194869
J Exp Med. 2008 Aug 4;205(8):1917-27
pubmed: 18663123
J Cell Biochem. 2009 Aug 1;107(5):857-64
pubmed: 19492306
Blood. 2016 Oct 20;128(16):2022-2032
pubmed: 27503502
Mol Ther. 2014 May;22(5):919-28
pubmed: 24434935
Stem Cells. 2006 Dec;24(12):2877-87
pubmed: 16960134
J Thromb Haemost. 2017 Sep;15(9):1717-1727
pubmed: 28752663
J Tissue Eng Regen Med. 2019 Feb;13(2):244-252
pubmed: 30556311
Blood Adv. 2019 Jan 8;3(1):72-82
pubmed: 30622145
J Biol Chem. 1999 Aug 13;274(33):23633-41
pubmed: 10438546
Stem Cell Reports. 2014 Nov 11;3(5):817-31
pubmed: 25418726
Cell Res. 2011 Mar;21(3):530-45
pubmed: 21221130
Nat Commun. 2017 Jun 15;8:15838
pubmed: 28643773
Virology. 1987 Jan;156(1):171-6
pubmed: 3643678
Development. 2003 Sep;130(18):4393-403
pubmed: 12900455
Cell. 2018 Jul 26;174(3):636-648.e18
pubmed: 30017246
Res Pract Thromb Haemost. 2020 Dec 03;5(1):111-124
pubmed: 33537535
Blood. 2001 Aug 1;98(3):618-26
pubmed: 11468159
Proc Natl Acad Sci U S A. 1996 Oct 29;93(22):12355-8
pubmed: 8901585
EMBO J. 1997 Jul 1;16(13):3965-73
pubmed: 9233806
Blood. 1998 Sep 1;92(5):1608-16
pubmed: 9716588
Platelets. 2017 Nov;28(7):649-656
pubmed: 28067095
Blood. 2009 Aug 27;114(9):1875-83
pubmed: 19525480
Blood. 2007 Apr 15;109(8):3297-9
pubmed: 17209061
Br J Haematol. 2017 Feb;176(3):365-394
pubmed: 28009056
Blood. 2007 Jun 15;109(12):5199-207
pubmed: 17317855
Blood. 2007 Feb 15;109(4):1433-41
pubmed: 17062726
Curr Trends Immunol. 2015;16:65-78
pubmed: 27818580
Blood. 2003 Jan 15;101(2):508-16
pubmed: 12393529
Cell Stem Cell. 2014 Apr 3;14(4):535-48
pubmed: 24529595
Arterioscler Thromb Vasc Biol. 2017 Jun;37(6):1076-1086
pubmed: 28428216
Lancet. 2013 May 25;381(9880):1866-75
pubmed: 23706803